Stock Financial Ratios

CFCOU / CF Corporation, Units financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)908.04
Enterprise Value ($M)245.32
Book Value ($M)5.00
Book Value / Share0.33
Price / Book49.09
NCAV ($M)691.21
NCAV / Share46.08
Price / NCAV-13.88
Income Statement (mra) ($M)
Net Income0.00
Balance Sheet (mrq) ($M)
Cash & Equivalents0.48
Cash / Share0.03
Quick Ratio1.41
Current Ratio1.41
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.00
Return on Assets (ROA)0.00
Return on Equity (ROE)0.00
Identifiers and Descriptors
Central Index Key (CIK)1668428
Industry Groups
Share Statistics
Common Shares Outstanding (M)69.00
Scoring Models
Piotroski F Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Liabilities And Stock Equity Per Share46.64
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Debt Per Share0.00
Cash And Equivalents Per Share0.03
Inventory Per Share0.00
Equity Per Share0.33
Liabilities Per Share4.75
Assets Other Non Current Per Share0.00
Liabilities Current Per Share1.78
Intangibles Per Share0.00
Goodwill Per Share0.00
Additional Paid In Capital Per Share1.50
Property Plant And Equipment Net Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share0.39
Cash Per Share0.03
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Assets Per Share46.64
Property Plant And Equipment Per Share0.00
Retained Earnings Per Share-1.17
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00

Related News Stories

BRIEF-CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​

2017-11-20 reuters
* CF corp - ‍CF Corp intends to transfer listing of its ordinary shares and warrants to New York Stock Exchange​ Source text for Eikon: Further company coverage: (16-0)

Vertex Gets CHMP Recommendation for Orkambi Label Expansion

2017-11-13 zacks
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the Committee for Medicinal Products for Human Use ("CHMP") has recommended approval of a label expansion for Orkambi in Europe. The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis ("CF") who are aged between 6 and 11 years and have two copies of the F508del mutation. (63-1)

Vertex Pharmaceuticals, USG and J. Jill highlighted as Zacks Bull and Bear of the Day

2017-10-13 zacks
Chicago, IL – October 13, 2017 – Zacks Equity Research Vertex Pharmaceuticals (Nasdaq:(VRTX - Free Report)  – Free Report) as the Bull of the Day, USG Corporation (NYSE:(USG - Free Report)  – Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on J. Jill Inc. (NYSE:(JILL - Free Report) – Free Report). (110-0)

Bull of the Day: Vertex Pharmaceuticals (VRTX)

2017-10-13 zacks
Vertex Pharmaceuticals (VRTX - Free Report) is the leading biotechnology company with a treatment for cystic fibrosis (CF). The company holds a strong position in this market with two commercial products, Orkambi and Kalydeco. Early in August, Vertex had said that it expects its CF franchise to deliver revenues of $1.87 billion to $2.1 billion in 2017 including Orkambi revenues of $1.1 billion to $1. (90-0)

BRIEF-CF Corp and Fidelity & Guaranty Life report on status of merger

2017-10-07 reuters
* CF Corp - ‍review of acquisition by New York Department of Financial Services is progressing; parties anticipate closing acquisition by year end 2017​ Source text for Eikon: Further company coverage: (16-0)

CUSIP: G20307123